Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $6.3 in the last session, down -4.11% from day before closing price of $6.57. In other words, the price has decreased by -$4.11 from its previous closing price. On the day, 1.38 million shares were traded. AMLX stock price reached its highest trading level at $6.58 during the session, while it also had its lowest trading level at $5.98.
Ratios:
We take a closer look at AMLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 12.05 and its Current Ratio is at 12.05. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on June 24, 2025, initiated with a Buy rating and assigned the stock a target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 31 ’25 when FRATES JAMES M sold 10,896 shares for $3.47 per share. The transaction valued at 37,806 led to the insider holds 290,988 shares of the business.
Bedrosian Camille L sold 12,425 shares of AMLX for $43,082 on Mar 31 ’25. The Chief Medical Officer now owns 194,375 shares after completing the transaction at $3.47 per share. On Mar 31 ’25, another insider, Mazzariello Gina, who serves as the Chief Legal Officer of the company, sold 9,192 shares for $3.48 each. As a result, the insider received 31,954 and left with 187,969 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 561588992 and an Enterprise Value of 368708352. Its current Enterprise Value per Revenue stands at -289.865 whereas that against EBITDA is -1.783.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.48, which has changed by 2.8181818 over the last 52 weeks, in comparison to a change of 0.12677538 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $7.27, while it has fallen to a 52-week low of $1.62. The 50-Day Moving Average of the stock is 19.03%, while the 200-Day Moving Average is calculated to be 45.08%.
Shares Statistics:
According to the various share statistics, AMLX traded on average about 1.26M shares per day over the past 3-months and 2899700 shares per day over the past 10 days. A total of 89.08M shares are outstanding, with a floating share count of 65.31M. Insiders hold about 26.74% of the company’s shares, while institutions hold 80.20% stake in the company. Shares short for AMLX as of 1749772800 were 4039910 with a Short Ratio of 3.22, compared to 1747267200 on 4972837. Therefore, it implies a Short% of Shares Outstanding of 4039910 and a Short% of Float of 5.0.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
